Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy

OBJECTIVE: To compare total medical costs and utilization over a 12-month period in commercially insured patients receiving FDA-approved adjunctive atypical antipsychotics (aripiprazole, olanzapine, or quetiapine) for depression. METHODS: A retrospective claims analysis was conducted from 2005–2010...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Nadkarni, Anagha, Kalsekar, Iftekhar, You, Min, Forbes, Robert, Hebden, Tony
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2013
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553650/
https://ncbi.nlm.nih.gov/pubmed/23378778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S36526
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak